Related Experiment Video
Updated: Jul 6, 2026
09:11
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Histone deacetylase inhibitors in lymphoma and solid malignancies
Walid Rasheed1, Mark Bishton, Ricky W Johnstone
1Division of Haematology & Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Melbourne, Victoria 8006, Australia. walid.rasheed@petermac.org
Expert Review of Anticancer Therapy
|March 28, 2008
Summary
Histone deacetylase inhibitors (HDACi) show promise as cancer treatments, with clinical trials demonstrating effectiveness in lymphomas and solid tumors. HDACi exhibit a favorable toxicity profile, supporting their expanding therapeutic role.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Histone deacetylase inhibitors (HDACi) are a novel class of antineoplastic agents.
- Preclinical studies demonstrate significant antitumor activity across various malignancies.
- HDACi are advancing rapidly through clinical development, including Phase I-III trials.
Purpose of the Study:
- To review recent advancements in the clinical development of HDACi.
- To discuss the current therapeutic applications of HDACi in lymphoma and solid tumors.
Main Methods:
- Review of preclinical and clinical data on HDAC inhibitors.
- Analysis of clinical trial outcomes for HDACi in various cancer types.
- Evaluation of toxicity profiles and response rates.
Main Results:
- Favorable clinical responses observed in cutaneous T-cell lymphoma and other lymphomas.
- Emerging evidence of clinical activity in solid tumors with single-agent and combination therapies.
- Generally good toxicity profile reported for HDACi.
Conclusions:
- HDACi represent a promising therapeutic strategy in oncology.
- Clinical development of HDACi is progressing, with established roles in lymphoma and potential in solid malignancies.
- Further large-scale studies are warranted to fully elucidate the potential of HDACi.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...